Distinguished in Multiple Myeloma

Dr. Richard A. Nash

Hematology Oncology | Hematology | Oncology
Healthone Clinic Services - Oncology Hematology LLC
1721 E 19th Ave, Suite 300, 
Denver, CO 
41 Years of Experience
Distinguished in Multiple Myeloma
Healthone Clinic Services - Oncology Hematology LLC
1721 E 19th Ave, Suite 300, 
Denver, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Nash is a Hematologist Oncology specialist and a Hematologist in Denver, Colorado. Dr. Nash has been practicing medicine for over 41 years and is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Stiff Person Syndrome, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 36 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Multiple Myeloma.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
Hca Healthone Presbyterian St Lukes
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Rocky Mountain Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

HEALTHONE CLINIC SERVICES - ONCOLOGY HEMATOLOGY LLC
1721 E 19th Ave, Suite 300, Denver, CO 80218

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases
High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug, Other, Biological, Procedure
Study Drugs: Anti-Thymocyte Globulin, Carmustine, Cytarabine, Etoposide, Melphalan, Prednisone
Study Phase: Phase 2
A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Other, Drug, Biological, Procedure
Study Drugs: Anti-thymocyte globulin, Cyclophosphamide, Filgrastim, Mycophenolate mofetil, Plerixafor
Study Phase: Phase 2
A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2024
Intervention Type: Drug
Study Drugs: Elotuzumab, Pomalidomide, Dexamethasone
Study Phase: Phase 2
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
Enrollment Status: Completed
Publish Date: December 05, 2023
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Enrollment Status: Completed
Publish Date: April 12, 2023
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: January 02, 2020
Intervention Type: Drug, Radiation, Procedure, Other
Study Phase: Phase 2
Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis
Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis
Enrollment Status: Completed
Publish Date: June 04, 2018
Intervention Type: Drug, Radiation, Procedure, Other
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

37 Total Publications

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial.
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: August 05, 2024
Similar Doctors
Elite in Multiple Myeloma
Dr. Jeffrey V. Matous
Hematology Oncology | Oncology | Hematology
Elite in Multiple Myeloma
Dr. Jeffrey V. Matous
Hematology Oncology | Oncology | Hematology

Healthone Clinic Services - Oncology Hematology LLC

1721 E 19th Ave, Suite 300, 
Denver, CO 
 (0.1 miles away)
720-754-4800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeffrey Matous is a Hematologist Oncology specialist and an Oncologist in Denver, Colorado. Dr. Matous is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Waldenstrom Macroglobulinemia, Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

Elite in Multiple Myeloma
Dr. Peter A. Forsberg
Hematology Oncology | Hematology | Oncology
Elite in Multiple Myeloma
Dr. Peter A. Forsberg
Hematology Oncology | Hematology | Oncology

Healthone Clinic Services - Oncology Hematology LLC

1721 E 19th Ave, 200 Colorado Blood Cancer, 
Denver, CO 
 (0.1 miles away)
720-754-4800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Forsberg is a Hematologist Oncology specialist and a Hematologist in Denver, Colorado. Dr. Forsberg is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Waldenstrom Macroglobulinemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Forsberg is currently accepting new patients.

Elite in Multiple Myeloma
Dr. Tomer M. Mark
Hematology Oncology
Elite in Multiple Myeloma
Dr. Tomer M. Mark
Hematology Oncology
12605 E 16th Ave, University Of Colorado Hospital, 
Aurora, CO 
 (6.6 miles away)
720-848-0000
Languages Spoken:
English
See accepted insurances

Tomer Mark is a Hematologist Oncology provider in Aurora, Colorado. Dr. Mark is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nash's expertise for a condition
ConditionClose
    View All 23 Advanced Conditions
    View All 58 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile